Design, synthesis, and structure - Activity relationship studies of novel 6,7-locked-[7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta]-2,4,6-trienoic acids

Journal of Medicinal Chemistry

Volumn 46, Issue 19, 2003, Pages 4087-4103

  Michellys, Pierre Yves ^a,d   Ardecky, Robert J ^a   Chen, Jyun Hung ^a   D'Arrigo, Jennifer ^a   Grese, Timothy A ^b   Karanewsky, Donald S ^a,d   Leibowitz, Mark D ^a   Liu, Sha ^a   Mais, Dale A ^a   Mapes, Christopher M ^f   Montrose Rafizadeh, Chahrzad ^b   Ogilvie, Katheen M ^b,g   Reifel Miller, Anne ^b   Rungta, Deepa ^a   Thompson, Anthony W ^a,e   Tyhonas, John S ^a   Boehm, Marcus F ^a,c  

^a LIGAND PHARMACEUTICALS INC   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c BIOGEN   (United States)

^d GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION   (United States)

^e ROCHE BIOSCIENCE   (United States)

^f JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^g PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYL 6,7 (2,3 THIENYL) 7 [3 ETHYL 5 TERT BUTYL 6 (2,2 DIFLUOROETHOXY)BENZENE]PENTANE 2,4,6 TRIENOIC ACID; 3 METHYL 6,7 (2,3 THIENYL) 7 [3 ETHYL 5 TERT BUTYL 6 (3 FLUOROPROPOXY)BENZENE]PENTANE 2,4,6 TRIENOIC ACID; 3 METHYL 6,7 (2,3 THIENYL) 7 [3,5 DI TERT BUTYL 6 (3,3 DIFLUOROPROPOXY)BENZENE]PENTANE 2,4,6 TRIENOIC ACID; 3 METHYL 6,7 (2,3 THIENYL) 7 [3,5 DIISOPROPYL 6 (2,2 DIFLUOROPROPOXY)BENZENE]PENTANE 2,4,6 TRIENOIC ACID; 3 METHYL 6,7 (2,3 THIENYL) 7 [3,5 DIISOPROPYL 6 (2,2,2 TRIFLUOROETHOXY)BENZENE]PENTANE 2,4,6 TRIENOIC ACID; 3 METHYL 6,7 (2,3 THIENYL) 7 [3,5 DIISOPROPYL 6 (3 FLUOROPROPOXY)BENZENE]PENTANE 2,4,6 TRIENOIC ACID; 3 METHYL 6,7 (3,4 FURYL) 7 [3,5 DIISOPROPYL 6 (3 FLUOROPROPOXYBENZENE)PENTANE 2,4,6 TRIENOIC ACID; 3 METHYL 6,7 CYCLOHEXANEDIENYL 7 [3,5 DIISOPROPYL 6 (2,2 DIFLUOROETHOXY)BENZENE]PENTANE 2,4,6 TRIENOIC ACID; 3 METHYL 6,7 CYCLOHEXANEDIENYL 7 [3,5 DIISOPROPYL 6 (3 FLUOROPROPOXY)BENZENE]PENTANE 2,4,6 TRIENOIC ACID; 3 METHYL 6,7 CYCLOPENTENYL 7 [3,5 DIISOPROPYL 6 (2,2 DIFLUOROETHOXY)BENZENE]PENTANE 2,4,6 TRIENOIC ACID; 3 METHYL 6,7 CYCLOPENTENYL 7 [3,5 DIISOPROPYL 6 (3 FLUOROPROPOXY)BENZENE]PENTANE 2,4,6 TRIENOIC ACID; DRUG VEHICLE; ETHYL 3 METHYL 6,7 (2,3 THIENYL) 7 [3 ETHYL 5 TERT BUTYL 6 (2,2 DIFLUOROETHOXY)BENZENE]PENTANE 2,4,6 TRIENOATE; ETHYL 3 METHYL 6,7 (2,3 THIENYL) 7 [3 ETHYL 5 TERT BUTYL 6 (3 FLUOROPROPOXY)BENZENE]PENTANE 2,4,6 TRIENOATE; ETHYL 3 METHYL 6,7 (2,3 THIENYL) 7 [3,5 DI TERT BUTYL 6 (3,3 DIFLUOROPROPOXY)BENZENE]PENTANE 2,4,6 TRIENOATE; ETHYL 3 METHYL 6,7 (2,3 THIENYL) 7 [3,5 DIISOPROPYL 6 (2,2 DIFLUOROETHOXY)BENZENE]PENTANE 2,4,6 TRIENOATE; ETHYL 3 METHYL 6,7 (2,3 THIENYL) 7 [3,5 DIISOPROPYL 6 (2,2,2 TRIFLUOROETHOXY)BENZENE]PENTANE 2,4,6 TRIENOATE; ETHYL 3 METHYL 6,7 (3,4 FURYL) 7 [3,5 DIISOPROPYL 6 (3 FLUOROPROPOXY)BENZENE]PENTANE 2,4,6 TRIENOATE; ETHYL 3 METHYL 6,7 CYCLOHEXANEDIENYL 7 [3,5 DIISOPROPYL 6 (2,2 DIFLUOROETHOXY)BENZENE]PENTANE 2,4,6 TRIENOATE; ETHYL 3 METHYL 6,7 CYCLOHEXANEDIENYL 7 [3,5 DIISOPROPYL 6 (3 FLUOROPROPOXY)BENZENE]PENTANE 2,4,6 TRIENOATE; ETHYL 3 METHYL 6,7 CYCLOPENTENYL 7 [3,5 DIISOPROPYL 6 (2,2 DIFLUOROETHOXYBENZENE]PENTANE 2,4,6 TRIENOATE; ETHYL 3 METHYL 6,7 CYCLOPENTENYL 7 [3,5 DIISOPROPYL 6 (2,2,2 TRIFLUOROETHOXY)BENZENE]PENTANE 2,4,6 TRIENOATE; ETHYL 3 METHYL 6,7 CYCLOPENTENYL 7 [3,5 DIISOPROPYL 6 (3 FLUOROPROPOXY)BENZENE]PENTANE 2,4,6 TRIENOATE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RETINOID DERIVATIVE; RETINOID X RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; GLUCOSE METABOLISM; LIPID METABOLISM; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ALKENES; ANIMALS; BENZENE DERIVATIVES; CELL LINE; CERCOPITHECUS AETHIOPS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUG SYNERGISM; HYPOGLYCEMIC AGENTS; MALE; MICE; OCTANOIC ACIDS; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, RETINOIC ACID; RETINOID X RECEPTORS; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES; THIAZOLIDINEDIONES; THYROXINE; TRANSCRIPTION FACTORS; TRANSFECTION; TRIGLYCERIDES;

EID: 0141455873     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm020401k     Document Type: Article

References (50)

1. Sporn, M. B.; Roberts, A. B.; Goodman, D. S., Eds. The Retinoids, 2nd ed.; Ravens Press: New York, 1994.
2. (a) Orfanos, C. E.; Ehlert, R.; Gollnick, H. The Retinoids. A review of their clinical pharmacology and therapeutic use [review]. Drugs 1987, 34, 459-503.
3. (b) Boehm, M. F.; Heyman, R. A.; Patel, S.; Stein, R.; Nagpal, S. Retinoids: biological function and use in the treatment of dermatologigal diseases [review]. Exp. Opin. Invest. Drugs 1995, 4, 593-612.
4. (c) Orfanos, C. E.; Zouboulis, C. C.; Almond-Roesler, B.; Geilen, C. C. Current use and future potential role of retinoids in dermatology [reviewl. Drugs 1997, 53, 358-387.
5. (d) Walmsley, S.; Northfelt, D. W.; Melowsky, B.; Conant, M.; Friedman-Kien, A. E.; Wagner, B. Treatment of AIDS-related cutaneous Kaposi's arcoma with topical alitretinoin (9-cis-retinoic acid) gel. J. Acquired Immune Defic. Syndr. 1999, 22, 235-246.
6. (e) Cheng, S. X. A new rexinoid for cutaneous T-cell lymphoma. Arch. Dermatol. 2001, 137, 649-652.
7. (a) Smith, M. A.; Parkinson, D. R.; Cheson, B. D.; Friedman, M. A.; Retinoids in cancer therapy [review]. J. Clin. Oncol. 1992, 10, 839-864.
8. (b) Hong, W. K.; Sporn, M. B. Recent advances in chemoprevention of cancer. Science 1997, 278, 1073-1077 and references therein.
9. (c) Pfahl, M. Retinoid related molecules: new promises against lung and breast cancer. Exp. Opin. Invest. Drugs 1998, 7, 601-606.
10. (d) Bischoff, E. D.; Gottardis, M. M.; Moon, T. E.; Heyman, R. A.; Lamph, W. W. Beyond tamoxifen: the retinoid receptor-selective ligand LGD1069 (targretin) causes complete regression of mammary carcinomas. Cancer Res. 1998, 58, 479-484 and references therein.
11. (e) Sporn, M. B.; Suh, N. Chemoprevention of cancer. Carcinogenesis 2000, 21, 525-530 and references therein.
12. Rosen, J.; Day, A.; Jones, T. K.; Turner Jones, T.; Nadzan, A. M.; Stein, R. B. Intracellular receptors and signal transducers and activators of transcription superfamilies: novel targets for small-molecule drug discovery. J. Med. Chem. 1995, 38, 4855-4874.
13. Mangelsdorf, D. J.; Unesono, K.; Evans, R. M. The Retinoid Receptor. The Retinoids: Biology, Chemistry, and Medicine, 2nd ed.; Raven Press: New York, 1994; pp 319-349.
14. Schulman, I. G.; Crombie, D.; Bissonnette, R. P.; Cesario, R.; Roegner, K.; Shao, G.; Heyman, R. A. RXR-Specific Agonists and Modulators: A New Retinoid Pharmacology. Handbook of Experimental Pharmacology, Vol. 139; Springer-Verlag: Berlin, 1999; pp 215-235 and references therein.
15. (a) Willson, T. M.; Brown, P. J.; Sternbach, D. D.; Henke, B. R. The PPARs: From Orphan Receptors to Drug Discovery. J. Med. Chem. 2000, 44, 527-550 and references therein.
16. (b) Lehnard, J. M. PPARγ/RXR as a molecular target for metabolic diseases. Recept. Channels 2001, 7, 249-258.
17. (c) Jones, A. B. Peroxisome proliferator-activated receptor (PPAR) modulators: diabetes and beyond. Med. Res. Rev. 2001, 21, 540-552.
18. (d) Isserman, I.; Green, S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990, 347, 645-650.
19. (a) Stumvoll, M.; Haring, H. Insulin resistance and insulin sensitizers. Horm. Res. 2001, 55(suppl. 2), 3-13.
20. (b) Mukherkjee, R.; Davies, P. J. A.; Crombie, D. L.; Bischoff, E. D.; Cesario, R. M.; Jow, L.; Hamann, L. G.; Boehm, M. F.; Mondon, C. E.; Nazdan, A. M.; Paterniti, J. R.; Heyman, R. A. Sensitization of obese mice to insulin by retinoid X receptor agonists. Nature 1997, 386, 407-410.
21. (c) Faul, M. A.; Grese, T. A. Selective RXR modulators for the threatment of type 2 diabetes. Opin. Drug Discov. Dev. 2002, 5(6), 974-985.
22. Michellys, P. Y.; Ardecky, R. J.; Chen, J. H.; Crombie, D. L.; Etgen, G. ; Faul, M.; Faulkner, A. L.; Grese, T. A.; Heyman, R. A.; Karanewsky, D. S.; Klausing, K.; Leibowitz, M. D.; Liu, S.; Mais, D. A.; Mapes, C. M.; Marschke, K.; Reifel-Miller, A.; Ogilvie, K. M.; Rungta, D.; Thompson, A. W.; Tyhonas, J. S.; Boehm, M. F.. Small molecules RXR modulators for type 2 diabetes. J. Med. Chem., manuscript in press.
23. (a) Boehm, M. F.; Zhang, L.; Badea, B. A.; White, S. K.; Mais, D. E.; Berger, E.; Suto, C. M.; Goldman, M. E.; Heyman, R. A. Synthesis and Structure-Activity Relationships of Novel Retinoid X Receptor-Selective Retinoids. J. Med. Chem. 1994, 37, 2930-2941.
24. (b) Boehm, M, F.; Zhang, L.; Zhi, L.; McClurg, R.; Berger, E.; Wagoner, M.; ais, D. E.; Suto, C. M.; Davies, P. J. A.; Heyman, R. A.; Nazdan, A. M. Design and Synthesis of Potent Retinoid X Receptor Selective Ligands That Induce Apoptosis in Leukemia Cells. J. Med. Chem. 1995, 38, 3146-3155.
25. (c) Faul, M. M.; Ratz, A. M.; Sullivan, K. A.; Trankle, W. G.; Winneroski, L. L. Synthesis of Novel Retinoid X Receptor-Selective Retinoids. J. Org. Chem. 2001, 66, 5772-5782.
26. (d) Hamann, L. G. An efficient stereospecific synthesis of the dimer-selective retinoid X receptor modulator (2E, 4E, 6Z)-7-[5,6,7,8-tertrahydro-5,5,8,8-tetramethyl-2-(n-propoxy)naphthalen-3-yl] -3-methylocta-2,4,6-trienoic acid. J. Org. Chem. 2000, 65, 3233-3235.
27. (e) Cannan Koch, S. S.; Dardashti, L. J.; Hebert, J. J.; White, S. K.; Croston, G. E.; Flatten, K. S.; Heyman, R. A.; Nazdan, A. M. Identification of the first retinoic X receptor homodimer antagonist. J. Med. Chem. 1996, 39, 3229-3234.
28. Zhang, L.; Nazdan, A. M.; Heyman, R. A.; Love, D. L.; Mais, D. E.; Croston, G. E.; Lamph, W. W.; Boehm, M, F. Discovery of novel retinoic acid receptor agonists having potent antiproliferative activity in cervical cells. J. Med. Chem. 1996, 39, 2659-2663.
29. Farmer, L. J.; Jeong, S. E.; Kallel, A.; Canan Koch, S. S.; Croston, G. E.; Flatten, K. S.; Heyman, R. A.; Nazdan, A. M. Synthesis and structure-activity relationships of potent retinoid x receptor ligands., Bioorg. Med. Chem. Lett. 1997, 7, 2393-2398.
30. Vuligonda, V.; Lin, Y.; Chandraratna, R. A. S. Synthesis of highly potent RXR-specific retinoids: the use of a cyclopropyl group as a double bond isostere. Bioorg. Med. Chem. Lett. 1996, 6, 213-218.
31. Beard, R. L.; Colon, D. F.; Song, T. K.; Davies, P. J. A.; Kochhar, D. M.; Chandraratna, R. A. S. Synthesis and structure-activity relationships of retinoid x receptor selective diarylsulfide analogues of retinoic acid. J. Med. Chem. 1996, 39, 3556-3563.
32. Hibi, S.; Kikuchi, K.; Yohimura, H.; Nagai, M.; Tai, K.; Hida, T. Syntheses and structure-activity relationships of novel retinoid x receptor agonists. J. Med. Chem. 1998, 41, 3245-3252.
33. Umemiya, H.; Fukasawa, H.; Ebisawa, M.; Eyrolles, L.; Kawachi, E.; Eisenmann, G.; Gronemeyer, H.; Hashimoto, Y.; Shudo, K.; Kagechika, H. Regulation of retinoidal actions by diazepinyl-benzoic acids. Retinoid synergists which activate the RXR-RAR heterodimers. J. Med. Chem. 1997, 40, 4222-4234.
34. Pakala, R.; Benedict, C. R. Modulation of endothelial cell proliferation by retinoid x receptor agonists. Eur. J. Pharm. 1999, 385, 255-261.
35. (a) Dawson, M. I.; Jong, L.; Hobbs, P. D.; Cameron, J. F.; Chao, W.-R.; Pfahl, M.; Lee, M.-O.; Shroot, B.; Pfahl, M. Conformational effects on retinoid receptor selectivity. 2. Effects of retinoid bridging group on retinoid x receptor activity and selectivity. J. Med. Chem. 1995, 38, 3368-3383.
36. (b) De Vos, S.; Dawsom, M. I.; Holden, S.; Le, T.; Wand, A.; Cho, S. K.; Chen, D.-L.; Koeffler, H. P. Effect of receptor-selective ligands on proliferation of prostate cancer cells. The Prostate 1997, 32, 115-121.
37. (c) Dawson, M. I.; Zhang, X.-K. Discovery, and design of retinoic acid receptor and retinoid x receptor class- and subtype-selective synthetic analogues of all-trans-retinoic acid and 9-cis-retinoic acid. Curr. Med. Chem. 2002, 9, 623-637.
38. Vuligonda, V.; Thacher, S. M.; Chandraratna, R. A. S. Enantioselective syntheses of potent retinoid X receptor ligands: differential biological activities of individual antipodes. J. Med. Chem. 2001, 44, 2298-2303.
39. Miyauwa, N.; Suzuki, A. Palladium-catalysed cross-coupling reactions of organoboron compounds. Chem. Rev. 1995, 95, 2457-2483.
40. (a) Wada, A.; Nomoto, Y.; Tano, K.; Yamashita, E.; Ito, M. Synthesis of 9Z-9-substituted retinoic acids by palladium catalyzed coupling reaction of a vinyl triflate with alkenyl stannanes. Chem. Pharm. Bull. 2000, 49, 1391-1394.
41. (b) Pazos, Y.; De Lera, A. Stereoselective synthesis of 9-cis-retinoic acid by Suzuki reaction. Tetrahedron. Lett. 1999, 40, 8287-8290.
42. Dominguez, B.; Pazos, Y.; De Lera, A. R. Stereocontrolled synthesis of 6-s-cis- and 6-s-trans-locked 9Z-retinoids by hydroxyl-accelerated Stille coupling of (Z)-tri-n-butylstannylbut-2-en-1-ol and bicyclic dienyl triflates. J. Org. Chem. 2000, 65, 5917-5925.
43. (a) Bergstrom, D. E.; Mott, A. W.; De Clercq, E.; Balzarini, J.; Swartling, D. J. 3′,3′-difluoro-3′-deoxythymidine: comparison of anti-HIV actvity to 3′-fluoro-3′-deoxythymidine. J. Med. Chem. 1992, 135, 3369-3372.
44. (b) W. J. Middleton, New fluorinated reagents. Dialkylamino sulfur fluorides. J. Org. Chem. 1975, 40, 574-578.
45. Liu, S.; Ogilvie, K. M.; Klausing, K.; Lawson, M. A.; Jolley, D.; Danmei, L.; Bilakovics, J.; Pascual, B.; Hein, N.; Urcan, M.; Leibowitz, M. D. Mechanism of selective retinoid x receptor agonist-induced hypothyroidism in the rat. Endocrinology 2003, 143(8): 2880-2885.
46. See patent WO/02100813A2 and WO/0216331A1.
47. Michellys, P. Y.; Ardecky, R J.; Chen, J. H.; Crombie, D. L.; Etgen, G.; Faul, M.; Faulkner, A. L.; Grese, T. A.; Heyman, R. A.; Karanewsky, D. S.; Klausing, K.; Leibowitz, M. D.; Liu, S.; Mais, D. A.; Mapes, C. M.; Marschke, K.; Reifel-Miller, A.; Ogilvie, K. M.; Rungta, D.; Thompson, A. W.; Tyhonas, J. S.; Boehm, M. F. RXR Modulators. New Small Molecules for Type 2 Diabetes? Abstract no. 4 presented at the 223rd American Chemical Society Meeting, Orlando, Florida (April 7-11, 2002).
48. Mapes, C. M.; Ardecky, R. J.; Chen, J. H.; Crombie, D. L.; Etgen, G.; Faul, M.; Faulkner, A. L.; Grese, T. A.; Heyman, R. A.; Karanewsky, D. S.; Klausing, K.; Leibowitz, M. D.; Liu, S.; Mais, D. A.; Marschke, K.; Reifel-Miller, A.; Ogilvie, K. M.; Rungta, D.; Thompson, A. W.; Tyhonas, J. S.; Boehm, M. F.; Michellys, P. Y. RXR Modulators. Design, Synthesis and Hypoglycemic activity of New RXR-Selective Locked-Dienoic Acids. Abstract no. 5 presented at the 223rd American Chemical Society Meeting, Orlando, Florida (April 7-11 2002).
49. Boehm, M. F.; Zhang, L.; Badea, B. A.; White, S. K.; Mais, D. E.; Berger, E.; Suto, C. M.; Goldman, M. E.; Heyman, R. A. Synthesis and Structure-Activity Relationships of Novel Retinoid X Receptor-Selective Retinoids. J. Med. Chem. 1994, 37, 2930-2941.
50. Data collected in the solid state at room temperature. Unpublished results.